(Adds more ANSM comment)
PARIS, March 12 (Reuters) - The French drug regulator ANSM
said on Friday it agreed with the European Medicines Agency's
advice that AstraZeneca's coronavirus shot should continue to be
used in vaccination campaigns.
Denmark, Norway, Iceland and Bulgaria have suspended the use
of the shot following reports of blood clots in some people who
had been vaccinated.
EMA has said the number of clots is no higher than in the
general population, and AstraZeneca said on Thursday it had
found no evidence of increased risk of deep-vein thrombosis.
ANSM said only one case of blood clotting had been found in
France after an AstraZeneca shot, and there was no indication
that it was linked to the vaccine.
"The benefit/risk ratio of the vaccine remains positive",
ANSM said on its website.
The agency said it was evaluating the safety of all COVID-19
vaccines available in France and actively monitoring their
side-effects.
(Reporting by Jean-Stephane Brosse, Geert De Clercq and
Matthieu Protard; Editing by Kevin Liffey)